(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Peripheral T Cell Lymphomas pipeline constitutes 40+ key companies continuously working towards developing 40+ Peripheral T Cell Lymphomas treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Peripheral T Cell Lymphomas Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Peripheral T Cell Lymphomas Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Peripheral T Cell Lymphomas Market.
Some of the key takeaways from the Peripheral T Cell Lymphomas Pipeline Report:
- Companies across the globe are diligently working toward developing novel Peripheral T Cell Lymphomas treatment therapies with a considerable amount of success over the years.
- Peripheral T Cell Lymphomas companies working in the treatment market are Applied Therapeutics, Autolus, Akeso Biopharma, Astex Pharmaceuticals, Secura Bio, Innate Pharma, Dizal Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology, Daiichi Sankyo, Affimed Therapeutics, Autolus Limited, Astex Pharmaceuticals, Kymera Therapeutics, Dialectic Therapeutics, PersonGen Biotherapeutics, and others, are developing therapies for the Peripheral T Cell Lymphomas treatment
- Emerging Peripheral T Cell Lymphomas therapies in the different phases of clinical trials are- AT-104, Auto 5, AK 104, Tolinapant, Duvelisib, Lacutamab, AZD 4205, Mitoxantrone liposomal, Valemetostat, AFM13, AUTO4, Tolinapant, KT-333, DT2216, TAA13 CAR T, and others are expected to have a significant impact on the Peripheral T Cell Lymphomas market in the coming years.
- In November 2022, Affimed N.V. and Artiva Biotherapeutics Inc. have unveiled a new collaborative partnership focused on the collective development, production, and commercialization of a combination therapy. This treatment combines Affimed’s Innate Cell Engager (ICE) AFM13 with Artiva’s cord blood-derived, cryopreserved off-the-shelf allogeneic NK cell product candidate, AB-101. Affimed submitted a pre-IND meeting request to the FDA regarding the co-administered AFM13 and AB-101 combination therapy for relapsed/refractory (r/r) Hodgkin lymphoma (HL). The request included an exploratory arm aimed at assessing the combination in r/r CD30-positive peripheral T-cell lymphoma (PTCL) and exploring a potential path to registration. The FDA has responded to this request and is expected to provide feedback by Q1 2023.
- MT-101 is currently undergoing development as a treatment for relapsed and refractory CD5-expressing T-cell lymphomas. Myeloid Therapeutics disclosed in October 2022 that the US Food and Drug Administration (FDA) had granted Fast Track Designation to MT-101 for individuals with refractory or relapsed CD5+ peripheral T-cell lymphoma. Following the determination of the recommended Phase II dosage, Myeloid intends to commence a Phase II trial to bolster registration efforts for this particular patient group.
- In September 2022, Yingli Pharma recently revealed the dosing of the initial patient in a Phase II trial aimed at investigating a medication to manage peripheral T cell lymphomas, which represent a diverse and usually aggressive group of tumors. The trial involves administering linperlisib, a robust inhibitor targeting the delta isoform of PI3 kinase, to patients with relapsed or refractory peripheral T/NK cell lymphoma. This single-arm Phase II study aims to assess the safety, effectiveness, and pharmacokinetics of orally administered linperlisib. The trial is conducted as part of a strategic collaboration between Yingli Pharma and The University of Texas MD Anderson Cancer Center.
- In September 2022, The European Commission bestowed orphan drug status upon nanatinostat and valganciclovir (Nana-val) for their potential use as a therapeutic solution in patients diagnosed with peripheral T-cell lymphoma (PTCL). Nanatinostat specifically targets particular isoforms of class I HDACs, pivotal in the regulation of viral genes that are epigenetically suppressed in Epstein-Barr virus (EBV)-associated cancers. Currently, research is underway to explore the combined effects of nanatinostat with valganciclovir in clinical investigations.
- In June 2022, Kymera Therapeutics disclosed that the FDA has approved orphan drug designation for KT-333 intended for treating Peripheral T-cell Lymphoma (PTCL). KT-333 stands as a pioneering degrader of the transcriptional regulator STAT3. The activation of STAT3 has been identified as a crucial regulator in PTCL, and presently, there are no approved therapies specifically targeting this pathway for PTCL treatment.
- In April 2021, Secura Bio declared the accomplishment of enrolling 101 patients into the PRIMO study, which assesses Copiktra’s effectiveness in treating individuals experiencing relapsed or refractory Peripheral T-cell Lymphoma (PTCL). The successful enrollment marks a significant milestone in advancing the development of Copiktra as a potential treatment for T-cell lymphomas, a category for which it presently lacks an indication.
Peripheral T Cell Lymphomas Overview
In Western countries, 10%–15% of non-Hodgkin lymphomas (NHLs) are peripheral T-cell lymphoma (PTCL), a rare and heterogeneous group of clinically aggressive malignancies with a dismal prognosis. Compared to patients with B-cell lymphoma, patients with PTCLs exhibit more aggressive clinical features, such as B-symptoms, diffuse disease, extranodal disease, elevated serum lactate dehydrogenase (LDH) and beta-2-microglobulin levels, bulky disease, elevated Ki-67, and overexpression of p53.
Get a Free Sample PDF Report to know more about Peripheral T Cell Lymphomas Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/peripheral-t-cell-lymphomas-ptcl-pipeline-insight
Emerging Peripheral T Cell Lymphomas Drugs Under Different Phases of Clinical Development Include:
- AT-104: Applied Therapeutics
- Auto 5: Autolus
- AK 104: Akeso Biopharma
- Tolinapant: Astex Pharmaceuticals
- Duvelisib: Secura Bio
- Lacutamab: Innate Pharma
- AZD 4205: Dizal Pharmaceutical
- Mitoxantrone liposomal: CSPC ZhongQi Pharmaceutical Technology
- Valemetostat: Daiichi Sankyo
- AFM13: Affimed Therapeutics
- AUTO4: Autolus Limited
- Tolinapant: Astex Pharmaceuticals
- KT-333: Kymera Therapeutics
- DT2216: Dialectic Therapeutics
- TAA13 CAR T: PersonGen Biotherapeutics
Peripheral T Cell Lymphomas Route of Administration
Peripheral T Cell Lymphomas pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Intra-tumoral
- Molecule Type
Peripheral T Cell Lymphomas Molecule Type
Peripheral T Cell Lymphomas Products have been categorized under various Molecule types, such as
- Monoclonal antibodies
- Immunoglobulins
- Small molecules
- Pyrimidines
- Proteins and Peptides
- Product Type
Peripheral T Cell Lymphomas Pipeline Therapeutics Assessment
- Peripheral T Cell Lymphomas Assessment by Product Type
- Peripheral T Cell Lymphomas By Stage and Product Type
- Peripheral T Cell Lymphomas Assessment by Route of Administration
- Peripheral T Cell Lymphomas By Stage and Route of Administration
- Peripheral T Cell Lymphomas Assessment by Molecule Type
- Peripheral T Cell Lymphomas by Stage and Molecule Type
DelveInsight’s Peripheral T Cell Lymphomas Report covers around 40+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Peripheral T Cell Lymphomas product details are provided in the report. Download the Peripheral T Cell Lymphomas pipeline report to learn more about the emerging Peripheral T Cell Lymphomas therapies
Some of the key companies in the Peripheral T Cell Lymphomas Therapeutics Market include:
Key companies developing therapies for Peripheral T Cell Lymphomas are – Viracta Therapeutics, Autolus Therapeutics, Affimed Therapeutics, C4 Therapeutics, Kymera Therapeutics, Daiichi Sankyo, SciTech Development LLC, Celleron Therapeutics, Myeloid Therapeutics, Astex Pharmaceuticals, Citius Pharmaceuticals, Innate Pharma, Genor Biopharma Co., Ltd., CerRx, Inc., Dizal Pharmaceuticals, Kura Oncology, Inc., Secura Bio, Sorrento Therapeutics, Bristol-Myers Squibb, Shanghai Yingli Pharmaceutical, Ono Pharmaceutical, iCell Gene Therapeutics, Tessa Therapeutics, Merck Sharp & Dohme, Rhizen Pharmaceuticals, Bayer, Dialectic Therapeutics, and others.
Peripheral T Cell Lymphomas Pipeline Analysis:
The Peripheral T Cell Lymphomas pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Peripheral T Cell Lymphomas with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral T Cell Lymphomas Treatment.
- Peripheral T Cell Lymphomas key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Peripheral T Cell Lymphomas Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peripheral T Cell Lymphomas market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Peripheral T Cell Lymphomas drugs and therapies
Peripheral T Cell Lymphomas Pipeline Market Drivers
- Increase in incidences of PTCL, rising investment for the development of advanced technologies, surge in government initiatives to promote research and awareness about the disease are some of the important factors that are fueling the Peripheral T Cell Lymphomas Market.
Peripheral T Cell Lymphomas Pipeline Market Barriers
- However, high cost associated with the treatment, lack of skilled professionals for early diagnosis of the disease and other factors are creating obstacles in the Peripheral T Cell Lymphomas Market growth.
Scope of Peripheral T Cell Lymphomas Pipeline Drug Insight
- Coverage: Global
- Key Peripheral T Cell Lymphomas Companies: Applied Therapeutics, Autolus, Akeso Biopharma, Astex Pharmaceuticals, Secura Bio, Innate Pharma, Dizal Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology, Daiichi Sankyo, Affimed Therapeutics, Autolus Limited, Astex Pharmaceuticals, Kymera Therapeutics, Dialectic Therapeutics, PersonGen Biotherapeutics, and others
- Key Peripheral T Cell Lymphomas Therapies: AT-104, Auto 5, AK 104, Tolinapant, Duvelisib, Lacutamab, AZD 4205, Mitoxantrone liposomal, Valemetostat, AFM13, AUTO4, Tolinapant, KT-333, DT2216, TAA13 CAR T, and others
- Peripheral T Cell Lymphomas Therapeutic Assessment: Peripheral T Cell Lymphomas current marketed and Peripheral T Cell Lymphomas emerging therapies
- Peripheral T Cell Lymphomas Market Dynamics: Peripheral T Cell Lymphomas market drivers and Peripheral T Cell Lymphomas market barriers
Request for Sample PDF Report for Peripheral T Cell Lymphomas Pipeline Assessment and clinical trials
Table of Contents
1. Peripheral T Cell Lymphomas Report Introduction
2. Peripheral T Cell Lymphomas Executive Summary
3. Peripheral T Cell Lymphomas Overview
4. Peripheral T Cell Lymphomas- Analytical Perspective In-depth Commercial Assessment
5. Peripheral T Cell Lymphomas Pipeline Therapeutics
6. Peripheral T Cell Lymphomas Late Stage Products (Phase II/III)
7. Peripheral T Cell Lymphomas Mid Stage Products (Phase II)
8. Peripheral T Cell Lymphomas Early Stage Products (Phase I)
9. Peripheral T Cell Lymphomas Preclinical Stage Products
10. Peripheral T Cell Lymphomas Therapeutics Assessment
11. Peripheral T Cell Lymphomas Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Peripheral T Cell Lymphomas Key Companies
14. Peripheral T Cell Lymphomas Key Products
15. Peripheral T Cell Lymphomas Unmet Needs
16 . Peripheral T Cell Lymphomas Market Drivers and Barriers
17. Peripheral T Cell Lymphomas Future Perspectives and Conclusion
18. Peripheral T Cell Lymphomas Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Peripheral T Cell Lymphomas Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Viracta Therapeutics, Autolus Therapeutics, Affimed Therapeutics
